MX359516B - Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. - Google Patents
Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.Info
- Publication number
- MX359516B MX359516B MX2013011771A MX2013011771A MX359516B MX 359516 B MX359516 B MX 359516B MX 2013011771 A MX2013011771 A MX 2013011771A MX 2013011771 A MX2013011771 A MX 2013011771A MX 359516 B MX359516 B MX 359516B
- Authority
- MX
- Mexico
- Prior art keywords
- preventing
- methods
- extracellular matrix
- fibroblast proliferation
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a composiciones y métodos para prevenir o tratara una enfermedad, afección o proceso patológico caracterizado por la aberrante proliferación de fibroblasto y la deposición de matriz extracelular en un tejido de un sujeto. El método incluye administrar una cantidad terapéutica de una composición farmacéutica que comprende un polipéptido que tiene la secuencia de aminoácido YAPAAARQARAKALARQLGVAA (SEQ ID NO: 1) o uno de sus equivalentes funcionales, y un portador farmacéuticamente aceptable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161474370P | 2011-04-12 | 2011-04-12 | |
PCT/US2012/033368 WO2012142320A2 (en) | 2011-04-12 | 2012-04-12 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013011771A MX2013011771A (es) | 2014-07-30 |
MX359516B true MX359516B (es) | 2018-10-01 |
Family
ID=47006527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013011771A MX359516B (es) | 2011-04-12 | 2012-04-12 | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. |
Country Status (15)
Country | Link |
---|---|
US (2) | US9642888B2 (es) |
EP (1) | EP2696888B1 (es) |
JP (1) | JP6031510B2 (es) |
KR (1) | KR101862291B1 (es) |
CN (3) | CN108014340A (es) |
AU (1) | AU2012242768B2 (es) |
BR (1) | BR112013026313A8 (es) |
CA (2) | CA2832910C (es) |
DK (1) | DK2696888T3 (es) |
ES (1) | ES2711670T3 (es) |
HK (1) | HK1255005A1 (es) |
MX (1) | MX359516B (es) |
RU (1) | RU2620066C2 (es) |
SG (2) | SG194135A1 (es) |
WO (1) | WO2012142320A2 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007342674B2 (en) | 2007-01-10 | 2013-09-19 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
WO2009021137A2 (en) | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
US9327008B2 (en) * | 2008-12-10 | 2016-05-03 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
US9890195B2 (en) * | 2009-07-27 | 2018-02-13 | Purdue Research Foundation | MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
WO2011149964A2 (en) * | 2010-05-24 | 2011-12-01 | Moerae Matrix, Inc., | Methods for treating or preventing vascular graft failure |
US9890200B2 (en) * | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
CA2832910C (en) | 2011-04-12 | 2019-07-02 | Cynthia Lander | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
FR2976587B1 (fr) * | 2011-06-20 | 2015-04-03 | Basf Beauty Care Solutions F | Methode de dosage in vitro par technique immunologique |
WO2013134636A1 (en) | 2012-03-09 | 2013-09-12 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
CA2884802A1 (en) * | 2012-10-31 | 2014-05-08 | Galecto Biotech Ab | Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
RU2686101C2 (ru) * | 2013-03-12 | 2019-04-24 | Селтакссис, Инк. | Способы ингибирования лейкотриен- а4-гидролазы |
CA2906035A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
EP3607941A1 (en) | 2013-04-30 | 2020-02-12 | Otitopic Inc. | Dry powder formulations and methods of use |
RU2016140332A (ru) * | 2014-03-14 | 2018-04-16 | Мори Матрикс, Инк. | Композиции и способы предотвращения или лечения хронической дисфункции аллотрансплантата легкого (хдал) и идиопатического фиброза легких (ифл) |
US10336788B2 (en) * | 2014-04-17 | 2019-07-02 | Moerae Matrix, Inc. | Inhibition of cardiac fibrosis in myocardial infarction |
AU2015350151A1 (en) * | 2014-11-17 | 2017-06-01 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
CN107406489A (zh) * | 2015-01-08 | 2017-11-28 | 莫伊莱麦屈克斯公司 | Mk2抑制剂肽的制剂 |
WO2016145234A2 (en) * | 2015-03-12 | 2016-09-15 | Moerae Matrix, Inc. | Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
KR102507987B1 (ko) | 2017-09-22 | 2023-03-21 | 벡추라 인코포레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
CN107987128B (zh) * | 2017-11-17 | 2019-06-11 | 广东医科大学 | 一种功能多肽及其在制备防治肺纤维化药物中的应用 |
CA3100381A1 (en) * | 2018-05-17 | 2019-11-21 | Actuate Therapeutics, Inc. | Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors |
US10898484B2 (en) | 2018-05-31 | 2021-01-26 | Celltaxis, Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
CN110108883A (zh) * | 2018-10-27 | 2019-08-09 | 广州呼吸健康研究院 | 用于筛选与靶治疗ards患者的msc精准医学的标志物组合 |
CN109406795A (zh) * | 2018-11-20 | 2019-03-01 | 昆明医科大学 | 一种轻型脑外伤的血清分子诊断标记物及应用 |
WO2021040673A1 (en) * | 2019-08-26 | 2021-03-04 | Alain Martin | Methods for the treatment of chronic hypoxemia and inhibiting lung fibrosis in patients with pulmonary fibrosis with and without copd |
USD958124S1 (en) | 2019-12-16 | 2022-07-19 | Samsung Electronics Co., Ltd. | Television receiver |
USD978094S1 (en) | 2019-12-27 | 2023-02-14 | Samsung Electronics Co., Ltd. | Television receiver |
US11744807B2 (en) * | 2020-01-17 | 2023-09-05 | Sami-Sabinsa Group Limited | Therapeutic compositions and methods for pulmonary fibrosis |
CN112386682B (zh) * | 2020-02-12 | 2022-12-06 | 王斌 | 纤连蛋白在制备治疗新型冠状病毒肺炎药物中的应用 |
US20230127499A1 (en) * | 2020-03-30 | 2023-04-27 | Figene, Llc | Peptides and adjuvants for augmentation of fibroblast therapy for coronavirus |
US20230141224A1 (en) * | 2020-04-01 | 2023-05-11 | Figene, Llc | Fibroblast mediated expansion and augmentation of immune regulatory cells for treatment of acute respiratory distress syndrome (ards) |
US11505584B2 (en) * | 2020-04-21 | 2022-11-22 | Remodeless Cv Ltd | Therapy for reducing brain damage |
USD989726S1 (en) | 2020-12-03 | 2023-06-20 | Samsung Electronics Co., Ltd. | Television receiver |
USD989017S1 (en) | 2020-12-03 | 2023-06-13 | Samsung Electronics Co., Ltd. | Television receiver |
AU2021390125A1 (en) * | 2020-12-03 | 2023-06-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-connective tissue growth factor antibody |
WO2022147172A1 (en) * | 2020-12-30 | 2022-07-07 | Briotech, Inc. | Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions |
US20220296645A1 (en) * | 2021-03-22 | 2022-09-22 | Spiritus Therapeutics, Inc. | Diagnostic and therapeutic uses of compositions comprising purified, enriched potent exosomes containing disease-based and therapy based signature cargo |
CN113440431A (zh) * | 2021-08-02 | 2021-09-28 | 山西锦波生物医药股份有限公司 | 重组ⅲ型人源化胶原蛋白在头皮护理中的用途及包含其的头皮护理产品 |
CN114522221B (zh) * | 2022-02-28 | 2024-04-19 | 中国人民解放军陆军特色医学中心 | 分泌蛋白ctgf在用于制备治疗急性肺损伤药物中的应用 |
WO2023178169A2 (en) * | 2022-03-15 | 2023-09-21 | Anemoi Biotech Holdings, Inc. | Compositions and methods for treating the pathophysiology of severe viral infection |
CN116789751B (zh) * | 2023-08-22 | 2023-11-17 | 中国农业大学 | 预防和/或治疗纤维化疾病的多肽及其应用 |
CN117577330B (zh) * | 2024-01-15 | 2024-04-02 | 北京大学 | 预测非酒精性脂肪性肝病肝纤维化程度的装置及存储介质 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
FI79651C (fi) | 1982-10-08 | 1990-02-12 | Glaxo Group Ltd | Doseringsanordning foer medicin. |
US4811731A (en) | 1985-07-30 | 1989-03-14 | Glaxo Group Limited | Devices for administering medicaments to patients |
JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
JPH07506252A (ja) | 1992-04-24 | 1995-07-13 | エス・アール・アイ・インターナシヨナル | 真核細胞内でのイン・ビボ相同配列ターゲッティング |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
EP0733059B1 (en) | 1993-12-09 | 2000-09-13 | Thomas Jefferson University | Compounds and methods for site-directed mutations in eukaryotic cells |
US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
JP2002540850A (ja) | 1999-04-05 | 2002-12-03 | ファーマシューティカル ディスカバリー コーポレイション | 微粉形成のための方法 |
ATE545652T1 (de) | 1999-06-29 | 2012-03-15 | Mannkind Corp | Reinigung und stabilisierung von proteinen und peptiden in pharmaceutischen agentien |
AU2003223718B2 (en) | 2002-04-25 | 2007-08-16 | The Scripps Research Institute | Treatment and prevention of pulmonary conditions |
TWI430810B (zh) * | 2002-07-19 | 2014-03-21 | Abbott Lab S A | TNFα相關病症之治療 |
DK2260718T3 (en) * | 2003-11-25 | 2014-11-17 | Virginia Tech Intell Prop | Composition which an animal to be taken, for use in reducing MAP kinase activity |
MXPA06013250A (es) * | 2004-05-14 | 2007-02-28 | Abbott Lab | Inhibidores de quinasa como agentes terapeuticos. |
CA2575692C (en) | 2004-08-20 | 2014-10-14 | Mannkind Corporation | Catalysis of diketopiperazine synthesis |
KR20130066695A (ko) | 2004-08-23 | 2013-06-20 | 맨카인드 코포레이션 | 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염 |
CN101014321A (zh) | 2004-08-23 | 2007-08-08 | 曼金德公司 | 5型磷酸二酯酶抑制剂的肺部给予 |
CN101227918A (zh) * | 2005-04-29 | 2008-07-23 | 加州大学评议会 | 治疗以炎症反应为特征的病理的肽和肽模拟物 |
CN104324362B (zh) | 2005-09-14 | 2018-04-24 | 曼金德公司 | 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法 |
MX2008010721A (es) | 2006-02-22 | 2008-09-01 | Mannkind Corp | Un metodo para mejorar las propiedades farmaceuticas de microparticulas que contienen dicetopiperazina y un agente activo. |
US20080057129A1 (en) * | 2006-04-03 | 2008-03-06 | Lerner E I | Drug microparticles |
AU2007342674B2 (en) | 2007-01-10 | 2013-09-19 | Purdue Research Foundation | Polypeptide inhibitors of HSP27 kinase and uses therefor |
US8063094B2 (en) * | 2007-02-08 | 2011-11-22 | Boehringer Ingelheim International Gmbh | Anti-cytokine heterocyclic compounds |
US20080282320A1 (en) | 2007-05-11 | 2008-11-13 | Denovo Andrew | Security Compliance Methodology and Tool |
WO2009021137A2 (en) * | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
WO2009085191A2 (en) | 2007-12-21 | 2009-07-09 | Cabot Corporation | Syntactic foam compositions, pipelines insulated with same, and method |
AU2009322865B2 (en) * | 2008-10-20 | 2013-07-18 | Moerae Matrix, Inc. | Polypeptide for treating or preventing adhesions |
US9327008B2 (en) | 2008-12-10 | 2016-05-03 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
WO2011149964A2 (en) * | 2010-05-24 | 2011-12-01 | Moerae Matrix, Inc., | Methods for treating or preventing vascular graft failure |
CA2832910C (en) | 2011-04-12 | 2019-07-02 | Cynthia Lander | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
-
2012
- 2012-04-12 CA CA2832910A patent/CA2832910C/en not_active Expired - Fee Related
- 2012-04-12 SG SG2013075031A patent/SG194135A1/en unknown
- 2012-04-12 DK DK12771584.5T patent/DK2696888T3/en active
- 2012-04-12 MX MX2013011771A patent/MX359516B/es active IP Right Grant
- 2012-04-12 AU AU2012242768A patent/AU2012242768B2/en not_active Ceased
- 2012-04-12 CA CA3042808A patent/CA3042808A1/en not_active Abandoned
- 2012-04-12 EP EP12771584.5A patent/EP2696888B1/en not_active Not-in-force
- 2012-04-12 ES ES12771584T patent/ES2711670T3/es active Active
- 2012-04-12 RU RU2013150249A patent/RU2620066C2/ru not_active IP Right Cessation
- 2012-04-12 CN CN201711403446.9A patent/CN108014340A/zh active Pending
- 2012-04-12 CN CN201910892185.4A patent/CN111110850A/zh active Pending
- 2012-04-12 JP JP2014505291A patent/JP6031510B2/ja not_active Expired - Fee Related
- 2012-04-12 KR KR1020137029996A patent/KR101862291B1/ko active IP Right Grant
- 2012-04-12 US US13/445,759 patent/US9642888B2/en not_active Expired - Fee Related
- 2012-04-12 BR BR112013026313A patent/BR112013026313A8/pt not_active Application Discontinuation
- 2012-04-12 SG SG10201604560TA patent/SG10201604560TA/en unknown
- 2012-04-12 WO PCT/US2012/033368 patent/WO2012142320A2/en active Application Filing
- 2012-04-12 CN CN201280027012.2A patent/CN104302310A/zh active Pending
-
2017
- 2017-04-04 US US15/478,950 patent/US20190022169A1/en not_active Abandoned
-
2018
- 2018-11-06 HK HK18114121.3A patent/HK1255005A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
RU2620066C2 (ru) | 2017-05-22 |
ES2711670T3 (es) | 2019-05-06 |
MX2013011771A (es) | 2014-07-30 |
AU2012242768B2 (en) | 2017-10-12 |
CA2832910A1 (en) | 2012-10-18 |
CA2832910C (en) | 2019-07-02 |
US9642888B2 (en) | 2017-05-09 |
SG194135A1 (en) | 2013-11-29 |
BR112013026313A2 (pt) | 2016-12-27 |
WO2012142320A8 (en) | 2014-02-20 |
US20190022169A1 (en) | 2019-01-24 |
BR112013026313A8 (pt) | 2018-01-30 |
EP2696888A4 (en) | 2016-04-20 |
WO2012142320A2 (en) | 2012-10-18 |
AU2012242768A1 (en) | 2013-10-24 |
EP2696888A2 (en) | 2014-02-19 |
JP6031510B2 (ja) | 2016-11-24 |
KR20140063517A (ko) | 2014-05-27 |
CA3042808A1 (en) | 2012-10-18 |
SG10201604560TA (en) | 2016-07-28 |
HK1255005A1 (zh) | 2019-08-02 |
EP2696888B1 (en) | 2018-12-05 |
WO2012142320A3 (en) | 2015-06-11 |
RU2013150249A (ru) | 2015-05-20 |
JP2014533235A (ja) | 2014-12-11 |
DK2696888T3 (en) | 2019-03-25 |
CN108014340A (zh) | 2018-05-11 |
NZ616672A (en) | 2016-04-29 |
CN111110850A (zh) | 2020-05-08 |
KR101862291B1 (ko) | 2018-05-29 |
US20120263680A1 (en) | 2012-10-18 |
CN104302310A (zh) | 2015-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX359516B (es) | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. | |
NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
MX2017006372A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular. | |
WO2011149964A3 (en) | Methods for treating or preventing vascular graft failure | |
NZ621868A (en) | Growth hormone polypeptides and methods of making and using same | |
NZ591130A (en) | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof | |
NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
NZ600583A (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
RS54215B1 (en) | COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
NZ603028A (en) | Tfpi inhibitors and methods of use | |
MX336187B (es) | Metodo para tratar el mal de parkinson. | |
MX355446B (es) | Tratamiento de rinitis. | |
FI20115870A0 (fi) | Neuroprotektiiviset soluihin tunkeutuvat peptidit | |
RU2013126581A (ru) | Мутанты стрептокиназы и их ковалентно модифицированные формы | |
NZ708990A (en) | Method for activating helper t cell | |
EA200901067A1 (ru) | Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов | |
NZ590469A (en) | Treatment of rheumatoid arthritis with human beta defensins (1-4) | |
WO2008103378A3 (en) | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist | |
MX2015007402A (es) | Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos. | |
MX2017002476A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: MOERAE MATRIX, INC. |
|
FG | Grant or registration |